Strides Pharma Science

Strides Pharma Science Debt/Market Cap

The Debt to Market Capitalization Ratio of Strides Pharma Science (STAR.NS) as of Nov 22, 2026 is 23.79 %. In the previous year, Debt to Market Capitalization Ratio was 31.85 % — a change of -25.32% (lower).

Debt/Market Cap

23.79 %

YoY

-25.32%

Last updated:

Debt to Market Capitalization Ratio of Strides Pharma Science is 2025 23.79 % . Debt to Market Capitalization Ratio of Strides Pharma Science was 2024 31.85 % . It decreases by -25.32% lower compared to the previous year.

The Strides Pharma Science Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2018
31.89 INR
Jan 1, 2019
40.77 INR
Jan 1, 2020
28.28 INR
Jan 1, 2021
29.71 INR
Jan 1, 2022
38.28 INR
Jan 1, 2023
38.34 INR
Jan 1, 2024
31.85 INR
Jan 1, 2025
23.79 INR
The Strides Pharma Science Debt/Market Cap history
YEARDebt/Market CapYoY
23.79 %-25.32%
31.85 %-16.92%
38.34 %+0.15%
38.28 %+28.82%
29.71 %+5.08%
28.28 %-30.63%
40.77 %+27.84%
31.89 %-16.88%
38.36 %-14.40%
44.82 %+303.72%
11.10 %+60.50%
6.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strides Pharma Science Stock analysis

What does Strides Pharma Science do? Strides Pharma Science Ltd. generates revenue through the development, manufacturing, and distribution of IP-led generics and bio-pharmaceutical products across its Pharmaceutical and Bio-pharmaceutical segments. The company serves global markets including Africa, Australia, Asia (excluding India), North America, Europe, India, and Others, offering niche pharmaceutical products in various dosage forms such as liquids, creams, ointments, soft gels, sachets, tablets, and modified release formats. Its manufacturing units in Bengaluru, Puducherry, Chennai, Singapore, Milan, Florida, and Nairobi produce anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drugs, alongside soft gelatin capsules. The firm's revenue streams are derived from the sale of its IP-led niche pharmaceutical products to healthcare providers, distributors, and global pharmaceutical companies operating in the specified geographical segments. Key product categories include anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, which are distributed through its global manufacturing network. The company's focus on specialized drug segments ensures consistent demand from healthcare systems and institutions managing infectious diseases. Strides Pharma Science Ltd. targets healthcare institutions, distributors, and pharmaceutical companies in regions such as North America, Europe, India, and Africa, where infectious disease management requires specialized treatments. Its manufacturing presence in multiple countries supports direct market access and cost efficiency, enabling the delivery of affordable pharmaceutical solutions. The company's product portfolio emphasizes high-demand therapeutic areas, aligning with global health priorities for infectious disease treatment. Strides Pharma Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strides Pharma Science stock

Debt to Market Capitalization Ratio of Strides Pharma Science is 23.79 % in 2025.

Debt to Market Capitalization Ratio of Strides Pharma Science changed from 31.85 % to 23.79 %, representing a -25.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio Strides Pharma Science since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's Strides Pharma Science with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Strides Pharma Science

All Key Metrics — Strides Pharma Science